{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:25:43Z","timestamp":1792743943727,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1038\/s41379-021-00997-2","type":"journal-article","created":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T08:04:26Z","timestamp":1640937866000},"page":"962-971","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas"],"prefix":"10.1016","volume":"35","author":[{"given":"Dara S.","family":"Ross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly A.","family":"Devereaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David YunTe","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7310-7824","authenticated-orcid":false,"given":"Antonio","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Makker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9927-1270","authenticated-orcid":false,"given":"Britta","family":"Weigelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9127-6982","authenticated-orcid":false,"given":"Lora H.","family":"Ellenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7220-3996","authenticated-orcid":false,"given":"M. Herman","family":"Chui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-021-00997-2_bib1","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1097\/PGP.0000000000000491","article-title":"High-grade endometrial carcinomas: morphologic and immunohistochemical features, diagnostic challenges and recommendations","volume":"38","author":"Murali","year":"2019","journal-title":"Int. J. Gynecol. Pathol"},{"key":"10.1038\/s41379-021-00997-2_bib2","first-page":"177","article-title":"p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis","volume":"150","author":"Tashiro","year":"1997","journal-title":"Am. J. Pathol."},{"key":"10.1038\/s41379-021-00997-2_bib3","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/1097-0142(19940915)74:6<1778::AID-CNCR2820740621>3.0.CO;2-5","article-title":"Uterine papillary serous adenocarcinoma. A 10-case study of p53 and c-erbB-2 expression and DNA content","volume":"74","author":"Prat","year":"1994","journal-title":"Cancer"},{"key":"10.1038\/s41379-021-00997-2_bib4","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/jnci\/djs345","article-title":"Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses","volume":"104","author":"Kuhn","year":"2012","journal-title":"JNCI"},{"key":"10.1038\/s41379-021-00997-2_bib5","first-page":"3935","article-title":"Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies","volume":"57","author":"Tashiro","year":"1997","journal-title":"Cancer Res."},{"key":"10.1038\/s41379-021-00997-2_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Levine","year":"2013","journal-title":"Nature"},{"key":"10.1038\/s41379-021-00997-2_bib7","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"key":"10.1038\/s41379-021-00997-2_bib8","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1200\/JCO.1993.11.10.1936","article-title":"Clinical significance of HER-2\/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group","volume":"11","author":"Seshadri","year":"1993","journal-title":"J. Clin. Oncol"},{"key":"10.1038\/s41379-021-00997-2_bib9","doi-asserted-by":"crossref","first-page":"691","DOI":"10.5858\/arpa.2011-0168-RS","article-title":"HER2\/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications","volume":"136","author":"Hechtman","year":"2012","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1038\/s41379-021-00997-2_bib10","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2005.03.4827","article-title":"HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients","volume":"24","author":"Morrison","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1038\/s41379-021-00997-2_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies\u2014a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1038\/s41379-021-00997-2_bib12","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1038\/s41379-021-00997-2_bib13","unstructured":"National Comprehensive Cancer Network. Uterine neoplasms (Version 1.2020)"},{"key":"10.1038\/s41379-021-00997-2_bib14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J. Mol. Diagn."},{"key":"10.1038\/s41379-021-00997-2_bib15","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jmoldx.2016.09.010","article-title":"Next-generation assessment of human epidermal growth factor receptor 2 (ERBB2) amplification status: clinical validation in the context of a hybrid capture-based, comprehensive solid tumor genomic profiling assay","volume":"19","author":"Ross","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"10.1038\/s41379-021-00997-2_bib16","series-title":"Classification of Tumours 5th Edition - Female Genital Tumours.","author":"WHO.","year":"2020"},{"key":"10.1038\/s41379-021-00997-2_bib17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"131","author":"Wolff","year":"2007","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1038\/s41379-021-00997-2_bib18","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod. Pathol"},{"key":"10.1038\/s41379-021-00997-2_bib19","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41379-021-00746-5","article-title":"Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study","volume":"34","author":"Buza","year":"2021","journal-title":"Mod. Pathol"},{"key":"10.1038\/s41379-021-00997-2_bib20","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5858\/arpa.2020-0207-RA","article-title":"HER2 testing in endometrial serous carcinoma: time for standardized pathology practice to meet the clinical demand","volume":"145","author":"Buza","year":"2021","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1038\/s41379-021-00997-2_bib21","doi-asserted-by":"crossref","unstructured":"Chui, M. H. et al. Somatic intronic TP53 c.375+5G mutations are a recurrent but under-recognized mode of TP53 inactivation. J. Pathol. Clin. Res.https:\/\/doi.org\/10.1002\/cjp2.242 (2021).","DOI":"10.1002\/cjp2.242"},{"key":"10.1038\/s41379-021-00997-2_bib22","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1073\/pnas.1222577110","article-title":"Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma","volume":"110","author":"Zhao","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1038\/s41379-021-00997-2_bib23","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1093\/annonc\/mdw197","article-title":"PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab","volume":"27","author":"Loibl","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1038\/s41379-021-00997-2_bib24","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1158\/0008-5472.CAN-08-0380","article-title":"A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy","volume":"68","author":"Lee-Hoeflich","year":"2008","journal-title":"Cancer Res."},{"key":"10.1038\/s41379-021-00997-2_bib25","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/gcc.22113","article-title":"Marked heterogeneity of HER2\/NEU gene amplification in endometrial serous carcinoma","volume":"52","author":"Buza","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1038\/s41379-021-00997-2_bib26","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41379-020-00695-5","article-title":"Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays","volume":"34","author":"Robinson","year":"2021","journal-title":"Mod. Pathol."},{"key":"10.1038\/s41379-021-00997-2_bib28","doi-asserted-by":"crossref","unstructured":"Vermij L. et al. HER2 status in high-risk endometrial cancers (PORTEC-3): relationship with histotype, molecular classification, and clinical outcomes. Cancers (Basel)13https:\/\/doi.org\/10.3390\/cancers13010044 (2020).","DOI":"10.3390\/cancers13010044"},{"key":"10.1038\/s41379-021-00997-2_bib29","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2004.11.154","article-title":"Her-2\/neu overexpression and amplification in uterine papillary serous carcinoma","volume":"22","author":"Slomovitz","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1038\/s41379-021-00997-2_bib30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ygyno.2005.03.041","article-title":"Determination of HER2\/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization","volume":"98","author":"Santin","year":"2005","journal-title":"Gyn. Oncol"},{"key":"10.1038\/s41379-021-00997-2_bib31","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1158\/1078-0432.CCR-20-4436","article-title":"Clinicopathologic and genomic analysis of TP53-mutated endometrial carcinomas","volume":"27","author":"Momeni-Boroujeni","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1038\/s41379-021-00997-2_bib33","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ygyno.2021.02.015","article-title":"Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer","volume":"161","author":"Da Cruz Paula","year":"2021","journal-title":"Gyn. Oncol"},{"key":"10.1038\/s41379-021-00997-2_bib34","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/bjc.2015.306","article-title":"PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2\/neu overexpressing uterine serous carcinomas","volume":"113","author":"Black","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1038\/s41379-021-00997-2_bib35","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1038\/s41379-021-00997-2_bib36","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"10.1038\/s41379-021-00997-2_bib37","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ygyno.2004.09.050","article-title":"COX-2, c-KIT and HER-2\/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?","volume":"96","author":"Raspollini","year":"2005","journal-title":"Gyn. Oncol."},{"key":"10.1038\/s41379-021-00997-2_bib38","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41379-019-0358-x","article-title":"HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy","volume":"33","author":"Rottmann","year":"2020","journal-title":"Mod. Pathol"},{"key":"10.1038\/s41379-021-00997-2_bib27","first-page":"14","article-title":"HER-2\/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization","volume":"18","author":"Odicino","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1038\/s41379-021-00997-2_bib32","doi-asserted-by":"crossref","unstructured":"Cagaanan, A. et al. HER2 Expression in endometrial cancers diagnosed as clear cell carcinoma. Int. J. Gynecol. Pathol.https:\/\/doi.org\/10.1097\/PGP.0000000000000783 (2021).","DOI":"10.1097\/PGP.0000000000000783"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41379-021-00997-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41379-021-00997-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222000862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222000862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41379-021-00997-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:28:02Z","timestamp":1760228882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222000862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0893395222000862"],"URL":"https:\/\/doi.org\/10.1038\/s41379-021-00997-2","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-021-00997-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}